Versantis is a global, clinical-stage pharmaceutical company addressing the growing, un-met medical need in liver diseases. Our lead program VS-01 leverages our proprietary scavenging liposomes technology to timely reverse the multi-organ complications arising from liver cirrhosis. It was shown to be safe and well tolerated in a Ph1b study with positive efficacy outcomes, and is now ready to start Phase 2a clinical investigations. VS-01 was granted orphan drug designations by the FDA and EMA, which help streamlining its clinical development pathway.

News

28.12.2021 Change of leadership at Swiss deeptech startups (startupticker.ch)
11.03.2021 New appointments at life sciences startups (startupticker.ch)
29.09.2020 Switzerland's TOP biotech startups 2020 (venturelab.swiss)
14.09.2020 Strong Swiss delegation at Bio Europe (startupticker.ch)
23.07.2020 Prizes from around the world (startupticker.ch)
20.01.2020 10 Swiss Biotech Startups to Watch in 2020 (venturelab.swiss)
18.09.2019 Versantis obtain funds to fuel clinical trials (startupticker.ch)
23.08.2019 Versantis first drug enters clinical trials (startupticker.ch)

Milestones/News

01.06.2021 VS-01 main patent granted in Europe

Documents

Videos and Presentations


Trailer of the company


The product by the founders